Home/Pipeline/ALT-100 mAb

ALT-100 mAb

Acute Respiratory Distress Syndrome (ARDS)

Phase 2aActive

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Phase 2a

Status

Active

Company

Aqualung Therapeutics, Aqualung Therapeutics

About Aqualung Therapeutics

Aqualung Therapeutics is a private, clinical-stage biotech focused on high-need inflammatory and fibrotic diseases through its eNamptor™ platform. The company's lead asset, ALT-100, is a monoclonal antibody in Phase 2a development for Acute Respiratory Distress Syndrome (ARDS) and has received FDA clearance for a Phase 2a study in lung fibrosis. With recent non-dilutive funding from an NIH STTR grant and a pipeline targeting conditions with significant mortality, Aqualung is positioning itself in a large and underserved therapeutic market.

View full company profile

About Aqualung Therapeutics

View full company profile

Therapeutic Areas

Inflammatory Disease Fibrosis Critical Care

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
ACE2v2-Fc	Cyrus Biotechnology	Preclinical	Active
GEn-1124	GEn1E Lifesciences	Phase 2	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS	Sedana Medical	Investigator-Initiated Trial	Active
Research Grant: Effects of sevoflurane on lung water in ARDS	Sedana Medical	Investigator-Initiated Trial	Active